KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Dividends payables Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Eli Lilly (LLY) Operating Leases (2019)

Eli Lilly filings provide 1 years of Operating Leases readings, the most recent being $608.4 million for Q4 2019.

On a quarterly basis, Operating Leases changed N/A to $608.4 million in Q4 2019 year-over-year; TTM through Dec 2019 was $608.4 million, a N/A change, with the full-year FY2019 number at $608.4 million, changed N/A from a year prior.
Operating Leases hit $608.4 million in Q4 2019 for Eli Lilly, down from $611.5 million in the prior quarter.
In the past five years, Operating Leases ranged from a high of $621.9 million in Q1 2019 to a low of $503.3 million in Q2 2019.